AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Aura Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

May 28, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2019--

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019, at 2:00 p.m. Eastern Time in New York, NY.

About Aura Biosciences

Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit www.aurabiosciences.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005088/en/

CONTACT: Media:

David Rosen

Argot Partners

212.600.1902 |david.rosen@argotpartners.com

Investors:

Joseph Rayne

Argot Partners

617.340.6075 |joseph@argotpartners.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY OPTICAL

SOURCE: Aura Biosciences

Copyright Business Wire 2019.

PUB: 05/28/2019 07:00 AM/DISC: 05/28/2019 07:01 AM

http://www.businesswire.com/news/home/20190528005088/en

All contents © copyright 2019 The Associated Press.All rights reserved.